Erja

List of Publications by Year
in descending order

29 papers	614 citations	777949 13 h-index	685536 24 g-index
29 all docs	29 docs citations	29 times ranked	910 citing authors

#	Article	IF	Citations
1	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2022, 77, 1209-1210.	1.3	6
2	Clinical Origin and Species Distribution of Fusarium spp. Isolates Identified by Molecular Sequencing and Mass Spectrometry: A European Multicenter Hospital Prospective Study. Journal of Fungi (Basel,) Tj ETQq0 0 0 rg BT /Overlock 10 Tf	1.5	12
3	Antifungal Susceptibility of 182 Fusarium Species Isolates from 20 European Centers: Comparison between EUCAST and Gradient Concentration Strip Methods. Antimicrobial Agents and Chemotherapy, 2021, 65, e0149521.	1.4	9
4	Human Plasma Protein Levels Alter the In Vitro Antifungal Activity of Caspofungin; an Explanation to the Effect in Critically Ill?. Mycoses, 2021, , .	1.8	0
5	CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection. Tuberculosis, 2020, 123, 101959.	0.8	3
6	Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Medicine, 2020, 12, 27.	3.6	58
7	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. Journal of Antimicrobial Chemotherapy, 2020, 75, 1807-1819.	1.3	37
8	Estimated burden of fungal infections in Sweden. Mycoses, 2019, 62, 1043-1048.	1.8	8
9	A new mathematical model to identify contacts with recent and remote latent tuberculosis. ERJ Open Research, 2019, 5, 00078-2019.	1.1	1
10	Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
11	Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. Journal of Antimicrobial Chemotherapy, 2018, 73, 2838-2845.	1.3	16
12	Minimum inhibitory concentration distributions for Mycobacterium avium complexâ€"towards evidence-based susceptibility breakpoints. International Journal of Infectious Diseases, 2017, 55, 122-124.	1.5	43
13	Susceptibility testing breakpoints for<i>Mycobacterium tuberculosis</i>categorize isolates with resistance mutations in<i>gyrA</i>as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB. Journal of Antimicrobial Chemotherapy, 2016, 71, 333-338.	1.3	13
14	Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B. Fungal Biology and Biotechnology, 2015, 2, 1.	2.5	37
15	Induction of Gliotoxin Secretion in Aspergillus fumigatus by Bacteria-Associated Molecules. PLoS ONE, 2014, 9, e93685.	1.1	19
16	Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting. International Journal of Mycobacteriology, 2013, 2, 103-108.	0.3	8
17	Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis. International Journal of Mycobacteriology, 2012, 1, 177-179.	0.3	4
18	The GenoType^{Â®} MTBDR<i>plus</i> assay for detection of drug resistance in <i>Mycobacterium tuberculosis</i> in Sweden. Apmis, 2012, 120, 405-409.	0.9	14

#	Article	IF	Citations
19	Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia. Journal of Antimicrobial Chemotherapy, 2008, 61, 1309-1311.	1.3	11
20	Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration. Journal of Antimicrobial Chemotherapy, 2004, 54, 940-943.	1.3	12
21	Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scandinavian Journal of Infectious Diseases, 2004, 36, 855-859.	1.5	16
22	New Automated Method for Determining Postantifungal Effect of Amphotericin B against Candida Species: Effects of Concentration, Exposure Time, and Area under the Curve. Antimicrobial Agents and Chemotherapy, 2002, 46, 4016-4018.	1.4	11
23	Trends in Antifungal Susceptibility among Swedish Candida Species Bloodstream Isolates from 1994 to 1998: Comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A Reference Method. Journal of Clinical Microbiology, 2001, 39, 4181-4183.	1.8	44
24	Candida glabrata Prosthesis Infection Following Pyelonephritis and Septicaemia. Scandinavian Journal of Infectious Diseases, 1997, 29, 635-638.	1.5	34
25	In Vitro Susceptibility of Respiratory Isolates of Aspergillus species to Itraconazole and Amphotericin B. Acquired Resistance to Itraconazole. Scandinavian Journal of Infectious Diseases, 1997, 29, 509-512.	1.5	90
26	Comparison of broth macrodilution, broth microdilution and Eâ€•test susceptibility tests of <i>Cryptococcus neoformans</i> for fluconazole. Mycoses, 1997, 40, 423-427.	1.8	13
27	Oral Candida albicans Isolates with Reduced Susceptibility to Fluconazole in Swedish HIV-infected Patients. Scandinavian Journal of Infectious Diseases, 1995, 27, 391-395.	1.5	22
28	Fluconazole Failure in Two Cases of Disseminated Candidosis. Scandinavian Journal of Infectious Diseases, 1995, 27, 421-424.	1.5	1
29	Detection of Candida albicans DNA in Serum by Polymerase Chain Reaction. Scandinavian Journal of Infectious Diseases, 1994, 26, 479-485.	1.5	69